Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Pharmacogenomics J. Author manuscript; available in PMC 2012 August 1.
Published in final edited form as:
Pharmacogenomics J. 2012 August; 12(4): 297–305.
Published online 2011 March 1. doi: 10.1038/tpj.2011.5

Figure 3

An external file that holds a picture, illustration, etc.
Object name is nihms340428f3.jpg

Combined genotype frequencies subdivided by CYP2C19 loss-of-function allele carrier status (noncarriers vs carriers) and ABCB1 c.3435C>T genotype (C/C+C/T vs T/T) in the Ashkenazi Jewish (AJ) and Sephardi Jewish (SJ) populations. Genotype categories conferring an increased risk for clopidogrel nonresponsiveness are highlighted by gray bars and genotype categories conferring the highest risk are highlighted by black bars. Of note, 34% of AJ and 43% of SJ individuals carried CYP2C19 and ABCB1 genotypes with an increased or high risk for clopidogrel nonresponsiveness. Genotypes that included the CYP2C19*15 allele were not included in this analysis (see Table 3 and Supplementary Table S5). Statistically distinct CYP2C19 and ABCB1 genotype category frequencies were detected between the AJ and SJ populations (P<0.0001). Error bars represent 95% confidence intervals; n, number of subjects.

Images in this article

  • Figure 1
  • Figure 2
  • Figure 3
Click on the image to see a larger version.